Injury induced transient downregulation of endothelial miR-200b is required to jump-start wound angiogenesis but the underlying mechanisms remain unclear. To interrogate the transcriptional changes, single-cell RNA sequencing was performed on ∼15000 human endothelial cells following treatment with miR-200b inhibitor or its mimic. The 3’ scRNA-seq analysis was conducted using the Chromium single cell system (10x Genomics). Unsupervised clustering using CellRanger identified 13 cell clusters, few of which were miR-200b responsive. To verify the novel potential targets of miR-200b identified in endothelial cells, we used Stable Isotope Labelling by Amino acids in Cell culture (SILAC) based proteomic analysis using mass spectrometry. A total of 3818 proteins were detected which were then filtered using statistical cut-offs (p value < 0.05; % change > 10%) identifying 319 proteins targeted by miR-200b. To dissect mechanisms involved in vascular function post-miR-200b silencing in vivo, we generated miR-200b-429fl/fl-Tie2 Cre mice where endothelial miR-200b levels was depleted. The therapeutic significance of miR-200b inhibition was studied using ischemic hind limb in these mice. Perfusion imaging was performed using Laser Speckle Perfusion imaging. Color-coded perfusion maps were acquired at different time-points post-surgery (d3, d7, d10, d14) and average perfusion was calculated using PimSoft v1.4 software. Inhibition of endothelial miR-200b rescued hindlimb ischemia with improved perfusion (n=5). This rescue was associated with increased abundance of CD31+/vWF+ vasculogenic cells at the site of injury (n=5). This work identified miR-200b regulated endothelial cell clusters, the functionality of which are explained by SILAC proteomics. These findings provide insight into novel mechanisms explaining how transient inhibition of endothelial miR-200b helps switch vascular homeostasis into an angiogenic fate in response to injury.


K. Singh: None. E. Hernandez: None. M. Kumar: None. Y. Rustagi: None. S.K. Mohanty: None. A.S. Abouhashem: None. S. Khanna: None. S. Roy: None. C.K. Sen: None.


National Institutes of Health (GM108014); Eli Lilly and Company; Indiana Collaborative Initiative for Talent Enrichment (to C.K.S., S.R.)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at